Synlogic (SYBX) Enters Cancer Collaboration with Roche

Synlogic, Inc. SYBX announced that it has entered a new collaboration with large pharma company, Roche RHHBY. Synlogic will develop its Synthetic Biotic medicine, SYNB1891, in combination with Roche’s PD-L1 inhibitor, Tecentriq (atezolizumab), as a treatment for advanced solid tumors.